Most operating systems enforce process isolation through hardware protection mechanisms such as memory segmentation, page mapping, and differentiated user and kernel instructions. Singularity is a new ...

A collaborative study by scientists at the University of California, Riverside, and University of Southern California reports on how a process known as alternative splicing, often described as ...

The Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, Department of Biology, Massachusetts Institute of Technology, United States; ...

This important study uses single-neuron Patch-seq RNA sequencing to investigate the process by which RNA editing can produce protein diversity and regulate function in various cellular contexts. The ...

The novel IP-RPLC–HRMS method enhances antisense oligonucleotide analysis by minimizing adduct formation and in-source artifacts, supporting regulatory compliance. Pentylamine and HFIP combination ...

The Respiratory Syncytial Virus (RSV) is a significant agent linked to respiratory infections, representing a considerable health risk for vulnerable populations, including infants, older adults, and ...

A group of Australian scientists has uncovered a new way to fight some of the toughest cancers by targeting an overlooked cellular process called minor splicing. This tiny but vital mechanism turns ...

* Transcription-mediated amplification (TMA) tests and commercially available reverse transcription polymerase chain reaction (RT-PCR) tests specifically designed to omit/adapt RNA ...

Elegen, a global leader in next-generation DNA manufacturing, and Nutcracker Therapeutics, a global leader in next-generation RNA design and manufacturing, today announced the launch of a pilot ...

Elegen and Nutcracker Therapeutics launched a pilot program to demonstrate what they label the industry’s first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer ...

Fully cell-free process aims to further democratize personalized cancer therapeutic manufacturing with shorter turnaround times and negligible bioburden and endotoxin risks. SAN CARLOS, Calif. & ...

Fully cell-free process aims to further democratize personalized cancer therapeutic manufacturing with shorter turnaround times and negligible bioburden and endotoxin risks. As late-stage PCT clinical ...